RHUMBLINE ADVISERS

Position in LCTX — Lineage Cell Therapeutics, Inc.

CIK 1115418 BOSTON, MA

Position in LCTX

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$169,692

+$79,041 QoQ

Shares Held

129,536

-35.7% QoQ

Ownership

0.051%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#34

of 130 holders

Holding Since

Mar 2020

14 quarters on record

Voting authority Sole 34% Shared 0% None 66%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. LCTX ranks #255 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$169,692	129,536	-35.7%	Shares	Sole	2026-08-12
2025-03-31	$90,651	201,447	+9.9%	Shares	Sole	2025-05-29
2024-12-31	$91,677	183,355	-1.9%	Shares	Sole	2025-05-29
2024-09-30	$170,077	186,898	+41.1%	Shares	Sole	2024-11-12
2024-06-30	$132,491	132,491	+15.1%	Shares	Sole	2024-08-01
2024-03-31	$170,318	115,080	+3.3%	Shares	Sole	2024-05-09
2023-12-31	$121,487	111,456	+0.4%	Shares	Sole	2024-02-08
2023-09-30	$130,950	110,975	+6.6%	Shares	Sole	2023-11-09
2023-06-30	$146,762	104,087	+2.3%	Shares	Sole	2023-08-08
2022-03-31	$156,682	101,742	-15.5%	Shares	Sole	2022-05-12
2021-12-31	$295,063	120,434	+1.4%	Shares	Sole	2022-02-10
2021-09-30	$299,181	118,723	+5.5%	Shares	Sole	2021-11-12
2021-06-30	$320,667	112,515	-37.6%	Shares	Sole	2021-08-05
2020-03-31	$149,685	180,344	—	Shares	Sole	2020-05-06
No filing history on record for this holder in this stock.